Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | NMBR | P28336 | 3/20 | 0.40 |
| ▸ | FPR1 | P21462 | 2/20 | 0.40 |
| ▸ | GRPR | P30550 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6253540 | 0.93 | NMBR (0.38) | TACR1NMBRFPR1GRPRFPR2 | |
| SCHEMBL6252251 | 0.93 | NMBR (0.48) | TACR1NMBRFPR1GRPR | |
| SCHEMBL7092917 | 0.92 | FPR1 (0.37) | TACR1NMBRFPR1GRPRFPR2 | |
| SCHEMBL6252419 | 0.90 | TACR1 (0.40) | TACR1NMBRFPR1GRPRFPR2 | |
| SCHEMBL6251353 | 0.84 | MEN1 (0.35) | — | |
| SCHEMBL7636672 | 0.83 | GHSR (0.44) | TACR1NMBRFPR1GRPRFPR2 | |
| SCHEMBL6718194 | 0.83 | GHSR (0.44) | TACR1NMBRFPR1GRPRFPR2 | |
| SCHEMBL6252297 | 0.82 | NMBR (0.48) | TACR1NMBRFPR1GRPRMAPT | |
| SCHEMBL6990221 | 0.82 | NMBR (0.48) | TACR1NMBRFPR1GRPRMAPT | |
| SCHEMBL6251031 | 0.81 | ALDH1A1 (0.37) | NMBRFPR1GRPRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040110768-A1 | Bombesin receptor antagonists | WARNER-LAMBERT COMPANY LLC | 2004-06-10 | — | — | US | claimed |
| EP-1334102-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-08-13 | — | — | EP | claimed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| WO-2002040475-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | claimed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | claimed |
| US-20040110768-A1 | Bombesin receptor antagonists | WARNER-LAMBERT COMPANY LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1333829-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| WO-2002040022-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONIST | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20020058606-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058606-A1 | Treatment of sexual dysfunction | BRS3, GNRHR, VIPR2 | TACR1 57/4885NMBR 122/4885FPR1 607/4885 |
| US-20040110768-A1 | Bombesin receptor antagonists | NPY1R, BDKRB1, NPY2R | TACR1 61/4885NMBR 142/4885FPR1 139/4885 |
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | TACR1 262/4885NMBR 258/4885FPR1 632/4885 |
| US-20020169101-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | TACR1 262/4885NMBR 258/4885FPR1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.